You are here
Onglyza (saxagliptin) is a DPP-4 inhibitor, manufactured by AstraZeneca and approved by the U.S. Food and Drug Administration (FDA) in July 31, 2009 for the treatment of Type-2 diabetes. Saxagliptin helps the pancreas for the secretion of more insulin and thus stopping the liver from making excess sugar. Onglyza effectively controls blood sugar without causing any weight fluctuations.
There were studies conducted which showed results that people on Onglyza medications has higher risk of pancreatic cancer, increased risk of hospitalization for heart failure, thus the medication has ended up causing harm than a benefit to diabetes patients.
Major Complications by Onglyza include:
- Pancreatic cancer
- Acute pancreatitis inflammation)
- Severe Joint Pain
- Thyroid cancer
- Heart failure
On April 5, 2016, FDA issued a warning that Onglyza increases the risk of heart failure, especially for patients who already have heart disease or kidney problems. The warning was supported by results of the SAVOR clinical trial, which linked saxagliptin to a 27% increased risk of heart failure.
Evidence to be looked for in potential cases
- Usage of Onglyza in Medical and Pharmacy Records
- Duration of Onglyza usage in medical records
- Proof of injury and Treatment provided for injuries
Medical Record Review and claim validation of Onglyza case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.